$ERAS

Levi & Korsinsky said investors who bought Erasca, Inc. (NASDAQ: ERAS) shares between Jan. 14, 2025 and Apr. 26, 2026 may seek damages in a pending class action. The firm links ERAS’s ~53.9% drop and about $11.59 per share loss to April 27, 2026 disclosures about alleged patent infringement, a Grade 5 patient death, and limits of prior cross-study comparisons. Lead plaintiff deadline is Aug. 10, 2026.

Erasca, Inc. (Nasdaq: ERAS) said it closed an upsized public offering of 36,142,857 shares of common stock at $17.50 per share, including 4,714,285 shares from the underwriters’ option. Gross proceeds were about $632.5 million. Erasca plans to use net proceeds for R&D, working capital, and general corporate purposes.

Erasca Inc. (NASDAQ:ERAS) shares rose 8.94% to $19.50 after phase 1 data for ERAS-0015 in RAS-mutant solid tumors. In pancreatic cancer, tumors shrank 57% after eight weeks in 7 patients. Jefferies raised its price target 14% to $24 and reiterated a buy. Erasca launched a follow-on offering to raise up to about $632M.

Erasca, Inc. (Nasdaq: ERAS) priced an upsized public offering of 31,428,572 shares of common stock at $17.50 per share. The company expects gross proceeds of about $550.0 million, with a 30-day option for underwriters to buy up to 4,714,285 additional shares. Net proceeds will fund R&D and general corporate purposes; closing is expected July 15, 2026.

Erasca (Nasdaq: ERAS) updated preliminary Phase 1 AURORAS-1 data for ERAS-0015. In 2L+ KRAS G12X pancreatic cancer at 32 mg QD, it reported 57% uORR (N=7) and generally well-tolerated safety with no DLTs. In a panitumumab combo, no DLTs occurred in a 16 mg cohort. Company plans potential registration-enabling trials in lung and pancreatic cancers in 2027.

Erasca, Inc. (Nasdaq: ERAS) said it intends to launch a proposed underwritten public offering of $500 million of its common stock, with a 30-day option for underwriters to buy up to an additional $75 million. Net proceeds would fund R&D, working capital, and general corporate purposes, subject to market conditions.

Erasca (ERAS) shares fell 3.1% in after-hours after the clinical-stage oncology company proposed a $500 million underwritten public offering of common stock, with underwriters able to buy up to an additional $75 million. Net proceeds would fund R&D and working capital. The move followed updated Phase 1 ERAS-0015 data and Goldman Sachs coverage, amid a broader risk-off market after Trump reinstated an Iran shipping blockade.

Erasca, Inc. (NASDAQ:ERAS) shares fell about 12% after hours after the company proposed an underwritten public offering of $500 million of common stock, with a 30-day option for underwriters to buy up to an additional $75 million. Proceeds would fund R&D, working capital, and general corporate uses, subject to conditions.

Mizuho, via Investing.com, highlighted seven U.S. healthcare stocks for growth, citing clinical catalysts and operational updates. Price targets and ratings include EYPT $36, PCVX $163, ERAS $26, ARQT $35, LNTH $115, EHC $134, and SOLV $100. Key items include EYPT Phase 3 data in Aug 2026, PCVX Phase 3 in 4Q 2026, and LNTH PDUFA mid-Aug 2026.

Erasca, Inc. (NASDAQ: ERAS) is facing a securities class action after its shares fell about 48% ($9.25) following allegations that Revolution Medicines challenged Erasca’s ERAS-0015 patent claims and after disclosure of a patient death about a month after treatment. The suit seeks investors who bought ERAS shares Jan. 14, 2025–Apr. 26, 2026.